Efficacy and Safety Evaluation of JNJ-77242113 in Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study

The primary objective of this Phase 3 multicenter, randomized, double-blind, placebo-controlled study is to evaluate the **efficacy** of JNJ-77242113 in participants with moderate to severe **plaque psoriasis**. This objective is clinically relevant as it aims to determine the therapeutic potential of JNJ-77242113 in managing a condition characterized by chronic inflammation and significant impact on patients' quality of life. The study seeks to provide evidence on the effectiveness of this investigational drug, which could lead to improved treatment options for individuals suffering from this dermatological condition.

The clinical trial involves a total of **319 participants** diagnosed with **moderate to severe plaque psoriasis**. The study population includes both male and female subjects, aged 12 years and older, encompassing adolescents, adults, and the elderly. Participants were selected based on specific criteria, including a diagnosis of plaque psoriasis for at least 26 weeks prior to the study, with or without psoriatic arthritis. The trial population is characterized by a total Body Surface Area (BSA) of 10% or greater, a Psoriasis Area and Severity Index (PASI) of 12 or higher, and an Investigator's Global Assessment (IGA) score of 3 or more at both screening and baseline. The study includes individuals from a vulnerable population, although specific lifestyle considerations such as diet or physical activity are not detailed in the available data.

The clinical trial is a **Phase 3**, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of **JNJ-77242113** for the treatment of participants with moderate to severe plaque psoriasis. The trial involves a randomized withdrawal and retreatment approach. The primary objective is to assess the efficacy of JNJ-77242113 in achieving an Investigator's Global Assessment (IGA) score of 0 or 1 with a ≥2-grade improvement from baseline at Week 16, and a Psoriasis Area and Severity Index (PASI) 90 at the same time point. The trial is expected to commence recruitment on November 20, 2023, and conclude by June 14, 2027.

Participants will be involved in the study for a maximum treatment period of 156 weeks. The trial includes several key visits: an initial screening visit to confirm eligibility based on criteria such as age (≥12 years), diagnosis of plaque psoriasis for at least 26 weeks, and specific baseline scores for BSA, PASI, and IGA. Following the screening, participants will undergo randomization and receive either the active treatment or placebo. Follow-up visits will be scheduled to monitor efficacy and safety outcomes, with assessments conducted at regular intervals, including the primary endpoint evaluation at Week 16. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted.

Participants may be withdrawn from the study early if they experience significant adverse events, fail to adhere to the study protocol, or if the investigator deems it necessary for their safety. The study employs a double-blind design to ensure that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial's methodology is structured to provide robust data on the therapeutic potential of JNJ-77242113 in managing moderate to severe plaque psoriasis, contributing valuable insights into its clinical application.

The clinical trial involves the evaluation of **JNJ-77242113**, an experimental medication, for the treatment of moderate to severe plaque psoriasis. **JNJ-77242113** is administered in the form of a **film-coated tablet**. The active substance, also named **JNJ-77242113**, is a protein of other origin. The pharmaceutical form is a film-coated tablet, and the route of administration is oral. The dosing schedule and specific dosage in milligrams are not explicitly detailed in the provided data. The maximum treatment period for this medication is 156 days. The product is developed by Janssen-Cilag International N.V. and is not a pediatric formulation.

In addition to the experimental medication, the study includes a **placebo** as a comparator treatment. The placebo is also administered in the form of a film-coated tablet without the active substance **JNJ-77242113**. The placebo is used to maintain the double-blind nature of the study, ensuring that neither the participants nor the investigators know who is receiving the active treatment or the placebo. The route of administration for the placebo is oral, similar to the experimental medication. The placebo serves as a control to evaluate the efficacy and safety of **JNJ-77242113** in the study population.

The efficacy of JNJ-77242113 in the treatment of moderate to severe plaque psoriasis will be assessed in a Phase 3 multicenter, randomized, double-blind, placebo-controlled study. The primary endpoints for evaluating efficacy include achieving an **Investigator's Global Assessment (IGA)** score of 0 or 1, with a ≥2-grade improvement from baseline at Week 16, and achieving a **Psoriasis Area and Severity Index (PASI) 90** at Week 16. These endpoints are designed to measure significant improvements in the severity and extent of psoriasis symptoms.